HKSE · 6998.HK
Edding Genor Group Holdings Limited
HK$1.60+HK$0.03 (+1.59%)
Edding Genor Group Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 58.97% below the high.
Loading market information…
HKSE · 1244.HK · HKD
Stock price
Quote as of Oct 30, 2026, 07:38 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
3D Medicines Inc.’s quoted price sits in the lower half of its reported 52-week range, 60.83% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
Established in 2014 and headquartered in Qingdao, China, 3D Medicines Inc. is a biopharmaceutical company dedicated to the discovery, development, and market introduction of innovative oncology drugs and therapeutic candidates. Its core mission is to address diverse cancer types, primarily serving patients in Mainland China. The company's flagship product, Envafolimab, is a PD-L1 antibody administered via subcutaneous injection. This treatment is approved for advanced solid tumors characterized by microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) status in patients who have undergone previous therapies. Beyond its currently marketed drug, 3D Medicines boasts a robust development pipeline. Two significant candidates are currently undergoing Phase III clinical trials: 3D189, which targets multiple tumor indications, and 3D229 (a GAS6/AXL inhibitor), under investigation for non-small cell lung cancer, ovarian cancer, and kidney cancer. The company's Phase II pipeline includes 3D1001, designed to manage postoperative dental pain and tumor-related discomfort, and 3D1002, also aimed at oncology pain relief. Additionally, 3D185 is in Phase I clinical evaluation for locally advanced or metastatic solid tumors. Further promising candidates in earlier stages encompass 3D197 for multi-indication tumor immunotherapy, 3D011 for advanced malignant solid tumors, and 3D057 for various types of tumors.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:57 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$1.60+HK$0.03 (+1.59%)
Edding Genor Group Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 58.97% below the high.
HK$3.26-HK$0.07 (-1.95%)
BioDlink International Company Limited’s quoted price sits in the lower half of its reported 52-week range, 44.46% below the high.
HK$1.97-HK$0.10 (-4.84%)
Zhaoke Ophthalmology Limited’s quoted price sits in the lower half of its reported 52-week range, 48.96% below the high.
HK$6.40HK$0.00 (0.0%)
Sunho Biologics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 21.95% below the high.
HK$2.20-HK$0.03 (-1.35%)
JW (Cayman) Therapeutics Co. Ltd’s quoted price sits in the lower half of its reported 52-week range, 47.37% below the high.
HK$0.98+HK$0.01 (+1.03%)
Brii Biosciences Limited’s quoted price sits in the lower half of its reported 52-week range, 48.42% below the high.
HK$3.80HK$0.00 (0.0%)
Wuhan YZY Biopharma Co Ltd’s quoted price sits in the lower half of its reported 52-week range, 54.76% below the high.
HK$4.13HK$0.00 (0.0%)
Sirnaomics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 61.47% below the high.
